Literature DB >> 2013457

Immunohistochemical demonstration of epidermal growth factor and c-myc oncogene product in normal, benign and malignant thyroid tissues.

Y Mizukami1, A Nonomura, T Hashimoto, T Michigishi, M Noguchi, F Matsubara, N Yanaihara.   

Abstract

The expression of epidermal growth factor (EGF) and c-myc oncogene product was studied immunohistochemically in 65 benign and malignant human thyroids. Normal thyroid tissues were usually negative with each antibody. Benign and malignant neoplastic thyroid tissues demonstrated a high percentage of stained cells. However, there was no significant difference in positivity between benign and malignant neoplastic tissues. In Graves' disease 25% of the cases were positive for EGF, and 100% for c-myc product. The effect of EGF or c-myc expression on prognosis was also examined in 42 patients with papillary thyroid carcinoma. When the cases were divided into two groups with regard to their EGF staining score (highly-expressed and poorly-expressed groups), the frequency of highly-expressed tumours was significantly higher in the recurrence-positive group compared with the recurrence-free group (86% vs 57%), but there was no significant difference between the groups in respect of c-myc expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013457     DOI: 10.1111/j.1365-2559.1991.tb00808.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues.

Authors:  Dan Chen; Wenjing Qi; Pengxin Zhang; Hongwei Guan; Lifen Wang
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

2.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

3.  Immunohistochemical demonstration of c-myc oncogene product in middle ear cholesteatoma.

Authors:  A Holly; M Sittinger; J Bujia
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

4.  Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach.

Authors:  M Saegusa; Y Takano; H Kishimoto; G Wakabayashi; K Nohga; M Okudaira
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Anaplastic thyroid carcinoma.

Authors:  Augusto Taccaliti; Francesca Silvetti; Gioia Palmonella; Marco Boscaro
Journal:  Front Endocrinol (Lausanne)       Date:  2012-07-05       Impact factor: 5.555

6.  EGF and TGF-β1 Effects on Thyroid Function.

Authors:  Gabriella Mincione; Maria Carmela Di Marcantonio; Chiara Tarantelli; Sonia D'Inzeo; Arianna Nicolussi; Francesco Nardi; Caterina Francesca Donini; Anna Coppa
Journal:  J Thyroid Res       Date:  2011-06-13

7.  Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells.

Authors:  Koichi Ohno; Tomohiro Shibata; Ken-Ichi Ito
Journal:  Cancer Sci       Date:  2022-07-12       Impact factor: 6.518

8.  Prognostic impact of EGF-receptor in papillary thyroid carcinoma.

Authors:  L A Akslen; A O Myking; H Salvesen; J E Varhaug
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

9.  cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis.

Authors:  Hany I Sakr; Deborah J Chute; Christian Nasr; Charles D Sturgis
Journal:  Diagn Pathol       Date:  2017-10-03       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.